Lung Cancer Treatment Improved Survival in New Trial
Patients with small cell lung cancer saw survival benefits from a novel B7-H3-targeted antibody-drug conjugate.
Updated on Sept. 22, 2026 in Cancer
Live Poll
Does international collaboration in clinical research lead to better treatment outcomes for patients globally?
Results from the ARTEMIS-008 clinical trial show that a new B7-H3-targeted antibody-drug conjugate, HS-20093, successfully extended overall survival for patients with second-line small cell lung cancer. These findings were presented at the 2026 World Conference on Lung Cancer in Seoul.
Why it matters
This development offers a potential alternative to conventional chemotherapy for small cell lung cancer, an area where standard treatments have historically provided limited survival benefits. The research aligns with broader efforts to integrate targeted biopharmaceuticals into oncology care.
The ARTEMIS-008 trial, a clinical study, demonstrated that the antibody-drug conjugate HS-20093 extends survival in patients with second-line small cell lung cancer. The primary endpoint of the study was overall survival, marking a departure from traditional chemotherapy-based approaches.
The players
Wang Jie
Director of the Department of Internal Medicine at the Cancer Hospital of the Chinese Academy of Medical Sciences who presented the trial results.
Cancer Hospital of the Chinese Academy of Medical Sciences
A premier oncology research institution in China that led the primary clinical research for the ARTEMIS-008 trial.
The details
HS-20093 functions as an antibody-drug conjugate designed to target B7-H3, a protein frequently expressed on the surface of tumor cells. By delivering a therapeutic payload directly to these cancer cells, the drug aims to destroy the tumor while minimizing exposure to healthy tissue. This mechanism contrasts with traditional chemotherapy, which impacts rapidly dividing cells throughout the body indiscriminately.
Timeline
September 12-15, 2026: The 2026 World Conference on Lung Cancer took place in Seoul.
Health Landscape
This development represents a shift toward precision medicine in the treatment of small cell lung cancer. It follows a pattern established by China's 15th Five-Year Plan which prioritizes biopharmaceuticals as a strategic industry.
Patients currently undergoing treatment for small cell lung cancer should discuss their eligibility for clinical trials with their oncologist. As this drug is investigated for potential use in other solid tumors, staying informed through your physician remains the best way to track emerging options.
The takeaway
Targeted therapies like HS-20093 are changing the standard of care for previously difficult-to-treat cancers. If you or a loved one are navigating a lung cancer diagnosis, ask your care team about current clinical trial opportunities and whether targeted antibody-drug conjugates may be appropriate.
Further reading
For more on the latest developments in oncology, visit our Cancer section.
Source note: This article includes information reported by IOL.
Live Poll
Does international collaboration in clinical research lead to better treatment outcomes for patients globally?
